FDA finalises psychedelic clinical trial guidance

The FDA is holding a public hearing to talk through psychedelic clinical trial guidance on 14 September. The FDA is holding a public hearing to talk through psychedelic drug development on 14 September. The FDA guidance details how sponsors should conduct clinical trials, as well as preclinical evaluations, of psychedelics. Credit: ZenkyPhoto / Shutterstock.com The US Food and Drug Administration (FDA) has finalised its formal guidance for clinical trials involving psychedelic drugs. The FDA document details recommendations for trial design, participant safety, abuse potential, and data collection. In conjunction with the guidance, the FDA and Department of Health and Human…

Source: Clinical Trials Arena